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Abstract
Several hurdles must be overcome in order to achieve efficient and safe immunotherapy against conformational
neurodegenerative diseases. In prion diseases, the main difficulty is that the prion protein is tolerated as a self protein,
which prevents powerful immune responses. Passive antibody therapy is effective only during early, asymptomatic disease,
well before diagnosis is made. If efficient immunotherapy of prion diseases is to be achieved, it is crucial to understand
precisely how immune tolerance against the prion protein can be overcome and which effector pathways may delay disease
progression. To this end, we generated a transgenic mouse that expresses the ß-chain of a T cell receptor recognizing a PrP
epitope presented by the class II major histocompatibility complex. The fact that the constraint is applied to only one TCR
chain allows adaptation of the other chain according to the presence or absence of tolerogenic PrP. We first show that
transgene-bearing T cells, pairing with rearranged a-chains conferring anti-PrP specificity, are systematically eliminated
during ontogeny in PrP+ mice, suggesting that precursors with good functional avidity are rare in a normal individual.
Second, we show that transgene-bearing T cells with anti-PrP specificity are not suppressed when transferred into PrP+
recipients and proliferate more extensively in a prion-infected host. Finally, such T cells provide protection through a cell-
mediated pathway involving IL-4 production. These findings support the idea that cell-mediated immunity in
neurodegenerative conditions may not be necessarily detrimental and may even contribute, when properly controlled,
to the resolution of pathological processes.
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Introduction
Prion diseases, also termed transmissible spongiform encepha-
lopathies (TSE), are fatal neurodegenerative disorders against
which no treatment is available yet. The key pathogenic event is
the conversion of the cellular prion protein (PrPc), a ubiquitous,
host-encoded glycoprotein, into a misfolded protein, PrP scrapie
(PrPSc) [1]. PrPSc forms oligomers that are self-propagating and
cause neuronal damage. PrPSc is the presumed prion agent which
is necessary and sufficient for disease transmission and gives strain-
associated characteristics [2].
Many recent reports have shown that mice treated with
antibodies (Abs) against PrP [3,4,5] or vaccinated against the
protein [6,7,8] acquire resistance to scrapie peripheral infection.
Encouraging as these findings may be, the results against TSE are
not fully satisfactory yet and have precluded clinical trials. On one
hand, passive Ab therapy is effective under restricted conditions,
notably before neurological symptoms appear [4]. On the other
hand, active vaccination is limited by the strong tolerogenicity of
self PrP [9,10]. With a few exceptions [6], vaccinated mice enjoyed
only limited remission and ultimately succumbed to prion
infection.
Focusing TSE immunotherapy on CD4
+ T cells rather than on
Ab-producing cells may overcome these difficulties [11]. Two
strategies borrowed from cancer immunotherapy have already
been probed for that purpose: dendritic cell (DC) vaccination [12]
and adoptive CD4
+ T cell therapy [13]. Improving T-cell-based
immunotherapy, however, requires deeper insights into several
issues. The way the anti-PrP repertoire is selected in the thymus
and the chances that anti-PrP T cells with good functional avidity
may overcome negative selection must be evaluated. One must
also understand the way such lymphocytes, whether generated in
the host or adoptively transferred, can be activated by prion-
infected cells and neutralize prion progression. To address these
issues, we have produced a transgenic (Tg) mouse expressing a
single T cell receptor (TCR) b-chain from an anti-PrP TCR. The
a-chains rearrange freely so that the anti-PrP repertoire adapts to
the antigenic context. This model made it possible to follow
PLoS Pathogens | www.plospathogens.org 1 September 2011 | Volume 7 | Issue 9 | e1002216repertoire development in PrP+ and PrP– mice through analysis of
the a-chain rearrangements, and to produce highly enriched
populations of T helper (Th) cells. The therapeutic efficiency of
those T cells was assessed following adoptive transfer.
Results
Phenotypic and Functional Characterization of TCR-b Tg
Mice on PrP+ or PrP–Backgrounds
Among three founders, only one B6 male (Figure 1A) over-
expressed the transgenic beta variable (BV) 12
+ rearrangement in
peripheral blood cells (29.8% versus 2.5% in controls, data not
shown), and transmitted this phenotype to its progeny. Spleens and
lymph nodes (LN) of Tg mice had normal size and normal total
white cell content. Spleens of PrP+ and PrP– Tg mice contained
9065610
6 and 9266610
6 cells versus 9668610
6 cells for spleens
of wild type (WT) littermates (n=5, data not shown). Tg mice on
both PrP+ and PrP– backgrounds displayed a minor reduction in
the relative percentage of CD4
+ T cells compared to CD8
+ T and
total B cells (Figure S1), suggesting that the expression of the TCR
transgene had a slight impact on T cell ontogeny, as also reported
in other TCR-Tg lines [14]. Secondary lymphoid organs from Tg
mice showed fully developed germinal centers and the presence of
cells with strong cell-surface PrPc expression (Figure S2A,B). The
expression of PrPc was also similar in the brain between WT mice
and Tg PrP+ mice, as assessed by immunohistochemistry and by
FACS analysis (Figure S3A,B). Therefore, the transgenic insertion
of the TCR b-chain in affects neither the architecture of secondary
lymphoid organs nor PrPc expression.
As shown in Figure 1B, the BV12
+ rearrangement was still
dominant in the third generation of mice raised on PrP+ or PrP–
backgrounds. The fact that endogenous rearrangements were not
excluded and that only a third of total CD4
+ T cells were BV12
+
suggested a belated expression of the transgene due to the nature
of the cassette. This inference was confirmed by flow cytometry
analysis of thymocytes from Tg mice showing an increase in the
percentage of transgenic BV12
+ rearrangements only after they
reach the single positive stage (Figure 1C). The expression of the b-
chain transgene in the SP8 subset resulted from the deletion of the
Cd8 gene silencer, which is present in the original plasmid, but
which happens to be excised during the construction process [15].
Figure 1D shows the respective percentages of transgene-
bearing CD4
+ and CD8
+ LN lymphocytes in several PrP+ and
PrP– Tg mice. Percentages of BV12
+ T cells were practically
identical in PrP– and PrP+ mice, and the higher percentage of
transgene expression among CD8
+ LN T cells confirms the known
preferential affinity of BV12
+ rearrangements for MHC class I
products during thymic selection [16].
As reported [9,10], PrP+ WT mice do not normally respond to
PrP. Because PrP+ Tg mice expressed a high percentage of TCR b-
chain rearrangements, we decided to examine whether, in contrast
to WT mice, these mice would be responsive. As Figure 2A shows,
in vivo primed T cells from Tg mice proliferated weakly and to the
same extent as T cells from WT littermates. Therefore, either
pairings with alpha rearrangements conferring anti-PrP reactivity
were deleted, or PrP-responders escaping selection weresuppressed,
notably by regulatory T (Treg) cells [17]. To test the latter
possibility, TgPrP+ micewereinvivo deprived of Treg cellsby anti-
CD25
+ T cell Ab (clone PC61) before being primed with PrP158–187
4 days later. CD4
+ T cells deprived of Treg lymphocytes proli-
ferated more vigorously than untreated controls in response to
antigenic challenge, but within the same range as non-Tg
littermates similarly deprived of Treg cells (Figure 2B). Treg
blockade therefore did not reveal the specific presence of PrP
responders within the pool of transgene-bearing T cells.
The situation was remarkably different in PrP– Tg mice. In vivo
primed CD4
+ T cells from these mice proliferated almost five
times as much upon in vitro challenge than non-Tg PrP– mice,
which also respond to the peptide [18] (Figure 2C). T cells
responded essentially to peptide PrP158–187 and only marginally to
an I-A
b-restricted peptide of ovalbumin (OVA323–339) (Figure 2D).
Conversely, priming CD4
+ T cells from Tg mice with OVA323–339
generated a modest, but specific response against ovalbumin which
suggests that a few non-PrP precursors are present in the total
CD4
+ repertoire of Tg mice (Figure 2D). PrP158–187-specific IFN-
c-producing CD4
+ T cells evaluated by ELISPOT were also
substantially increased in Tg versus non-Tg mice (Figure S4). No
IL-4 response could be detected under the same conditions,
suggesting an initial shift of anti-PrP T cells toward a Th1 profile.
A characteristic of biased T cell repertoires is their capacity to
respond to primary in vitro stimulation [19]. Naive CD4
+ T cells
from Tg mice did indeed proliferate in response to PrP158–187 in a
dose-dependent manner, in contrast to naive non-Tg T cells
(Figure 2E). Expansion of the anti-PrP repertoire in PrP– Tg mice
could also be evidenced by the fact that the percentage of BV12
+
T cells in LN underwent a substantial increase after peptide
priming (Figure S5).
Analysis of the a-chain Rearrangements Pairing with the
b-chain Transgene
To gain insight into the mechanisms of repertoire selection on
PrP+ and PrP– backgrounds, we analyzed the diversity of TCR a-
chain rearrangements among sorted CD4
+ BV12
+ T cells by
immunoscope. Figure S6 gives an overview of the 20 alpha variable
chain (TRAV) families associated with the b-chain transgene in
naiveandprimedTg mice.Table 1 showsthe actual percentages for
each family. TRAV family usage did not differ between PrP+ or
PrP– naive Tg mice. In particular, TRAV13, the variable segment
constitutive of the a-chain of the original hybridoma that had
donated the b-chain, was used to the same extent in the two Tg
progenies. The pattern changed in primed BV12
+ T cells. Whereas
TRAV13 usage in PrP+ primed mice was practically unmodified, it
represented almost 80% of all families in PrP– mice. Moreover, the
Author Summary
It is generally accepted that prion-specific antibodies can
protect against mouse scrapie infection. However, passive
antibody therapy is limited to the lymphoinvasion stage of
the disease. Active immunization has been attempted but
the results have been disappointing. There is therefore a
need for developing analytical models that will allow a fine
dissection of the immune mechanisms at play in prion
diseases and help distinguish between protective effects
mediated by B cells and antibodies, and the effect of T
cells. The aim of our study was to thoroughly examine T
cell tolerance to the prion protein and to evaluate whether
a pure specific population of T cells adoptively transferred
to a normal host could proliferate and confer protection
against scrapie. We designed a transgenic mouse in which
the majority of T lymphocytes recognize the prion protein.
Our key findings are that prion-specific T cells remain
functional when transferred to normal recipients, even
more so when the host is infected with scrapie, and confer
partial protection against the disease by slowing down
prion replication, in complete absence of anti-prion
antibodies. Anti-prion T cells may therefore be considered
as a therapeutic tool in the future.
Anti-prion T-cells against Scrapie
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(CDR3) followed a Gaussian distribution except for the rearrange-
ments in primed PrP– mice where the distribution presented a
predominant peak of 12 residues (Figure 3A). This CDR3 was
homogeneous enough to be sequenced directly from the PCR
product. The sequence was identical to the a-chain CDR3
expressed in the original TCR hybridoma (Figure 3B).
Fate of Transgene-bearing CD4
+ T Cells Transferred into
Normal or Infected Recipients
Primed Ly5.2
+ CD4
+ T cells from Tg PrP– donors were labeled
with carboxyfluorescein diacetate succinimidyl ester (CFSE) and
injected into Ly5.1
+ PrP+ and PrP– recipients. BV12
+ lymphocytes
amongLy5.2
+CD4
+gated T cellscollected after a3-day engraftment
into PrP+ hosts had markedly proliferated, as shown by the presence
of a resolved population in the upper left quadrant (Figure 4A). Far
fewer non-BV12 CD4+ T cells were seen in the lower left quadrant.
As expected, T cells injected into PrP– mice did not respond
(Figure 4B). The ‘‘% divided’’ measuring the number of lymphocytes
that had undergone mitosis and the average number of divisions per
cell (division index) was much higher in the BV12
+ than in the non-
BV12 subset, indicating that responders were considerably more
numerous and still reactive in the PrP+ environment (Figure 4C).
Next, we compared the proliferation of BV12
+ CD4
+ T cells in
prion-infected versus healthy mice (Figure 4D). Of interest, the
percentage of dividing T cells was strikingly higher in prion-
infected mice. The same trend can be observed in Figure 4E,
recapitulating data of more than 10 mice per group. Differences
were statistically significant between infected and normal recipient
mice (p,0.05 by ANOVA and Bonferroni’s two-by-two compar-
isons). Infected antigen presenting cells (APCs) reactivated anti-
PrP T cells more efficiently than non-infected APCs.
Figure 1. Expression of the TCR b-chain transgene in PrP+ and PrP– mice. (A) Genomic PCR from a founder mouse. (B) FACS analysis of LN
cells from Tg versus WT mice bred on a PrP+ or PrP– background showing histograms of the percentages of BV12
+ T cells in gated CD4
+ populations.
(C) Over-expression of the BV12
+ transgene starting at the single positive stage of thymic differentiation. Tg mouse (top row) and WT mouse (bottom
row). (D) BV12
+ cells within CD4
+ or CD8
+ LN T cells of Tg PrP+ and Tg PrP– mice. Each symbol represents an individual mouse. Horizontal bars show
medians. Differences within subsets are not significant.
doi:10.1371/journal.ppat.1002216.g001
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+ T cells from PrP+ or PrP– Tg mice. (A) Proliferation against PrP158–187 of PrP-primed CD4
+ T cells from Tg
(black circles) or WT (grey circles) PrP+ mice. T cells were collected 10 days after priming. Error bars show standard errors of triplicate cultures.
Cultures were pulsed at day 5. (B) Proliferation of PrP-primed T cells from Tg or WT PrP+ mice treated with PC61 or an isotype control. T cells were
challenged with 6 mM of PrP158–187. Cultures were arrested as in (A). (C) In vitro proliferation of PrP-primed CD4
+ T cells from Tg (black circles) or WT
(grey circles) PrP– mice. Cultures were pulsed at day 3. Error bars show standard error of triplicate cultures. (D) PrP-primed CD4
+ T cells from Tg mice
respond massively and specifically to peptide PrP158–187 but not to the irrelevant OVA323-339 peptide. Conversely, priming with OVA323–339 results in a
moderate response to the peptide. (E) Primary responses to PrP158–187 of naive T cells from Tg or WT PrP– mice. Numbers in legend correspond to
peptide concentrations present in the micro-cultures. Cultures were pulsed at day 5. Error bars show standard deviations of triplicate wells. Each
graph is representative of at least 3 independent experiments, with 3 to 4 mice per group.
doi:10.1371/journal.ppat.1002216.g002
Anti-prion T-cells against Scrapie
PLoS Pathogens | www.plospathogens.org 4 September 2011 | Volume 7 | Issue 9 | e1002216Adoptive Transfer of Limited Amounts of Transgene-
bearing CD4
+ T Cells Delays Scrapie Onset in Peripherally
Infected Mice
Having previously shown that PrP-sensitized polyclonal T cells
attenuate scrapie evolution [13], we undertook to confirm those
conclusions with transgene-bearing CD4
+ T cells. Two 610
5
CD4
+ BV12
+ primed T cells were transferred after sorting into
CD3e
o/o mice which had been infected 1 day before with 2610
4
LD50 of the prion strain 139A. Recipients of BV12
+ T cells were
boosted with peptide PrP158–187 one day after transfer and once
monthly thereafter or left non-boosted. Controls consisted of mice
transferred with sorted BV12-negative CD4
+ T cells further
boosted and of non-transferred mice. Neurological symptoms
appeared in two waves. Non-transferred mice and mice trans-
ferred with BV12-negative T cells became sick at 170 and 178.5
median day post-infection (dpi), respectively, whereas recipients of
BV12
+ T cells either boosted or not became sick at 217 and 197
median dpi, respectively (Figure 5A). One out of the 6 BV12
+ T
cell transferred and boosted mice remained free of symptoms
(Figure 5A). Differences in kinetics were statistically significant
among the four groups according to multivariate log rank test, as
well as between the two control groups compared to the two
experimental groups which had received BV12
+ T cells, but not
between boosted versus non-boosted recipients of transgene-
bearing T cells nor between the two control groups which
received BV12-negative T cells or no T cells. Overt disease
duration from onset to terminal stage was significantly longer in
the two experimental groups treated with BV12
+ T cells than in
the two control groups (42 median day versus 33 median day
respectively) (Figure 5B). Brains of mice culled at terminal stage
contained similar amounts of proteinase-K (PK) -resistant PrP,
irrespective of the nature of the T cell transfer, the clinical onset or
the overt disease duration (Figure S7A). This suggests that terminal
stage occurs when a sufficient amount of PK-resistant PrP has
accumulated in the brain. In contrast, PK-resistant PrP could not
be detected in the spleen and brain of the mouse which had
remained permanently free of neurological symptoms and was
sacrificed at 350 dpi (Figure S7B).
To get an insight on where T cells exert their prionostatic
effects, two types of experiments were performed. First, a few
experimental and control mice were sacrificed at 90 dpi in order to
compare the levels of PK-resistant PrP in their spleens by western
blot. Second, we looked for the presence of T cells in the brain of
the above mentioned mice sacrificed at 90dpi and of mice
sacrificed at terminal stage. As shown in Figure 6, 4 out of 6 spleen
samples of mice that had received BV12
+ CD4
+ T cells (either
boosted or non-boosted), were almost completely free of
pathological PrP, suggesting that anti-PrP T cells blocked the
propagation of PK-resistant PrP in peripheral lymphoid tissues. At
terminal stage, T cells were present in the brains of all mice which
had received BV12
+ T cells, whether boosted or non-boosted. At
90 dpi, one mouse transferred with BV12
+ T cells and boosted
already showed CNS infiltration. Fewer infiltrating T cells were
detected, even at terminal stage in the brains of mice that had
received BV12-negative T cells (Figure 7).
Humoral and Cell-mediated Anti-PrP Responses in
Adoptively Transferred Mice
Blood samples were collected at 90 dpi to assess the presence of
donor T cells in the CD3e
0/0 hosts (Figure S8). CD4
+ T cells were
clearly evidenced among the peripheral blood lymphocytes of
transferred mice. The expansion of BV12
+ CD4
+ T cells was
virtually identical in mice which had been boosted with peptide
PrP158–187 or in non-challenged mice.
Serum samples were collected at 90 and 120 dpi to monitor for
the presence of circulating Abs against native PrPc which
presumably convey protection (Figure 8A). Abs were barely
detectable in all serum samples, regardless of collection time and of
treatment. Transferred T cells therefore had not initiated a
Table 1. Relative percentages of TRAV family usage within
the TCR a-chains pairing with the transgenic TCR b-chain.
Tg naive Tg primed
PrP– PrP+ PrP– PrP+
AV1 0.0 0.0 0.0 0.4
AV2 0.0 0.0 0.0 0.2
AV3 0.9 0.7 0.0 4.2
AV4 2.4 31.7 10.5 6.2
AV5 5.1 0.0 0.0 0.9
AV6A 2.0 0.6 0.0 1.8
AV6B 2.7 0.7 0.0 1.2
AV7 11.5 14.9 1.1 27.7
AV8 4.0 4.0 0.0 3.2
AV9 24.7 7.2 3.2 16.0
AV10 1.8 0.1 0.0 0.8
AV11 7.5 0.1 0.0 1.1
AV12 3.8 9.8 4.7 9.8
AV13 25.2 25.9 79.8 15.6
AV14 3.3 3.9 0.7 7.5
AV15 0.0 0.0 0.0 0.5
AV16 0.0 0.1 0.0 0.6
AV17 2.5 0.8 0.0 1.3
AV18 0.0 0.0 0.0 0.0
AV19 0.0 0.0 0.0 0.4
AV21 2.6 0.3 0.0 0.5
doi:10.1371/journal.ppat.1002216.t001
Figure 3. Immunoscope analysis of TCR a-chains pairing with
the BV12
+ TCR b-chain. (A) Focus on CDR3 diversity of TRAV13
+
chains in naive or primed CD4
+ cells from PrP+ and PrP– mice. (B)
Identity between CDR3 sequences of TCR a-chains paired with the
BV12
+ TCR b-chain in PrP– mice and the CDR3 sequence of the original
TCR a-chain identified in the T cell hybridoma. Each experiment is
representative of 2 or 3 independent analyses, with a pool of at least 3
mice per test.
doi:10.1371/journal.ppat.1002216.g003
Anti-prion T-cells against Scrapie
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looked at antigen-specific T-cell proliferation and lymphokine
secretion at 120 dpi. Engrafted BV12
+ T cells could still proliferate
in response to PrP158–187 (Figure 8B). A substantial proportion of T
cells also released IL-4 after antigenic challenge, as evidenced by
ELISPOT (Figure 8C), but at variance with freshly activated anti-
PrP T cells, long-term engrafted lymphocytes were low producers
of IFN-c (Figure 8D). Contrasting with those low values, control T
cells stimulated with concanavalin A displayed a frequency of IFN-
c secretors in the range of 200 spots per 1610
5 cells (data not
shown).
Discussion
The mechanisms at work in prion immunotherapy are still
poorly understood. Abs against PrP or PrP receptors have been
Figure 4. In vivo proliferation of CD4
+ BV12
+ cells. (A) Dot-plot of CFSE-labeled CD4
+ T cells after 3-day engraftment in mice boosted with
PrP158–187. Cells were gated in a Ly5.2
+ window. (B) Same cells as in (A) but transferred into non-loaded PrP– mice. (C) Proliferation statistics on CD4
+
BV12
+ and BV12
- T cells displayed in (A). (D) Modelized representation of T cell divisions in various recipients. Digits in each histogram represent the
‘‘% Divide’’. (E) Division indexes of CD4
+ BV12
+ cells transferred into various recipients: PrP– (n=8), PrP+ (n=11), peptide-loaded PrP– (n=11), prion-
infected (n=12). Each symbol represents a single mouse. Horizontal bars show the means. Differences between the infected mice and the other
groups were significant by one-way analysis of variance (p,0.005) and by Bonferroni’s multiple comparison tests.
doi:10.1371/journal.ppat.1002216.g004
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demonstration that they cured infected cell lines in vitro [20,21]
and retarded disease progression in vivo [3,4,5,22]. By contrast,
many authors have seen the involvement of T cells in
neurodegenerative conditions as counterproductive, based on the
fact that T cells may promote neuronal decay via microglia [23] or
initiate autoimmune complications such as reported in Alzheimer’s
disease patients [24]. Recent evidence suggests, however, that in
addition to providing help to B cells, CD4
+ T cells may also make
a contribution of their own against neurodegenerative conditions
[25].
Our first objective was to find out whether anti-PrP T cells with
good TCR functional avidity may escape central tolerance and be
available for active vaccination or adoptive therapy. With the use
of single b-chain Tg mice we were able to show how anti-PrP
precursors emerge in a PrP+ or negative environment. A first
conclusion is that the preselected PrP repertoire in the thymus is
tightly controlled, leaving little chance for lymphocytes with good
TCR avidity to escape selection and to settle in peripheral organs.
Although the percentages of transgene-bearing CD4
+ T cells in
PrP+ Tg mice are as high as in PrP– mice, their reactivity to PrP
peptide is as limited as that of T lymphocytes from non-Tg
littermates. The blockade of CD25
+ regulatory T cells prior to
antigenic challenge increased proliferation and IFN-c release to
the same extent as it did for T cells from non-Tg mice. Therefore,
Treg cells cannot presently account for the lack of responsiveness
of PrP+ Tg mice even though a regulation of anti-PrP precursors
by foxp3
+ T cells has been described [7]. The situation is totally
different in PrP– Tg mice in which CD4
+ T cells displayed strong
reactivity against the dominant PrP epitope. They proliferated
more vigorously upon antigenic challenge than non-Tg littermates,
producing more IFN-c and responding in vitro even without in
vivo priming. Although the TCR a/b repertoire against a given
antigenic specificity is generally considered to be highly diverse,
limited heterogeneity of b-chain rearrangements has been
reported [26,27,28]. Limited heterogeneity is also reflected by
the fact that the T cell repertoire of single TCR b-chain Tg mice is
frequently skewed toward the specificity of the TCR that provided
the rearranged chain [19]. But, as shown here, the b-chain is not
sufficient by itself to impart TCR specificity since BV12
+ T cells in
Figure 5. Adoptive transfer of minimal amounts of transgene-bearing CD4
+ T cells delays scrapie onset and prolongs the clinical
phase. (A) Disease onset in untreated controls (white circles, dotted line), in recipients of BV12-negative peptide-boosted T cells (grey circles, dotted
line), in non-boosted recipients of BV12
+ cells (grey diamonds, solid line), and in boosted recipients of BV12
+ cells (black diamonds, solid line).
Differences were significant between the 4 groups by multivariate log rank test (p=0.0073). They were also significant (p,0.005) between the two
control groups and the boosted plus non-boosted recipients of BV12
+ T cells. (B) The clinical phase of scrapie was significantly longer in mice
receiving BV12
+ CD4
+ T cells, whether boosted or non-boosted, compared with mice receiving BV12-negative CD4
+ T cells or left untreated (p,0.05
by Mann-Whitney test between the two groups receiving BV12
+ T cells and the two groups receiving BV12-negative T cells or no T cells).
doi:10.1371/journal.ppat.1002216.g005
Figure 6. Anti-PrP T cells prevent the accumulation of PK-
resistant PrP in secondary lymphoid organs. (A) Western blots of
spleen material at 90 dpi. (B) Normalization of western blots shown in
(A). Numbers above bars correspond to lanes in (A).
doi:10.1371/journal.ppat.1002216.g006
Anti-prion T-cells against Scrapie
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demonstrated, the a-chain makes an essential contribution to the
final specificity and determines ultimately whether a T cell
precursor responds or not to a defined epitope [28,29,30,31].
Central selection in PrP+ mice probably eliminates the alpha
pairings that confer anti-PrP responsiveness. This phenomenon is
all or none because a pairings that would result in TCRs of
intermediate avidity are visibly not spared either. Selection based
on the choice of a TCR a-chain rearrangement is one of many
strategies aimed at preventing autoreactivity [32]. A different
TCR b-chain transgene originating from a TCR with lower
functional avidity would possibly have allowed pairing with a-
chains conferring responsiveness, as evidenced by the generation
of activated T cells in normal WT mice challenged with
immunogenic formulations of PrP.
Immunoscope analyses confirmed those conclusions. No bias in
TRAV family usage was identified in naive CD4
+ BV12
+ T cells in
a PrP+ or -negative context. This indicates a wide variety of a
pairings among exiting T cells even though anti-PrP precursors are
already abundant in the naive repertoire of PrP– Tg mice, as
shown by primary in vitro responses. However, after antigen
selection, the distribution of TRAV families differed radically in
PrP+ and PrP– mice. TRAV13 usage in primed PrP+ Tg mice was
similar to that of naive mice, whereas TRAV13 usage became
predominant in primed T cells from PrP– Tg mice. Similar
changes in a-chain diversity after antigenic priming were
demonstrated in single-chain Tg mice challenged with lympho-
cytic choriomeningitis virus (LCMV) and in Tg non-obese diabetic
(NOD) mice spontaneously developing autoreactive T cells against
islets of Langerhans [29,30]. Noteworthy, this dominating
TRAV13 rearrangement showed a highly homogeneous CDR3
domain. The CDR3 nucleotide sequence was identical to that of
the a-chain isolated in the original T cell hybridoma. From a
practical point of view, this result shows that after antigen priming,
the BV12
+ T cell subset is composed of a quasi-monoclonal
population of anti-PrP effector cells. A similar result was described
in a single-chain Tg NOD mouse, in which CD8
+ T cells had
infiltrated the pancreas and had been activated locally [30].
Another valuable conclusion, from the perspective of adoptive T
cell therapy, is that anti-PrP T cells maintain their reactivity in a
PrP+ environment and are preferentially activated by prion-
infected cells. CFSE-labeled CD4
+ T cells from primed Tg mice
showed vigorous proliferation after a 3-day engraftment in PrP+
mice or in PrP– mice immunized with peptide. As expected, they
did not proliferate in non-challenged PrP– hosts, confirming that
the response was antigen specific and not caused by homeostatic
regulation [33]. Contrasting with the highly rigid selection at work
in the thymus, the periphery appears to be more permissive,
notably to primed T cells. As previously suggested [13], naive anti-
PrP precursors may be more receptive to peripheral regulation. It
Figure 7. Presence of infiltrating T cells in the brain of adoptively transferred mice. (A) Frozen sections of anterior, medium, and posterior
crosswise brain portions showing the presence lymphocytes staining positively with an anti-CD3 Ab. The EAE brain culled at the climax of MOG-
induced disease served as a positive control (40X). (B) Summary of infiltrating T cell frequencies in brains of adoptively transferred mice. Each circle
represents the frequencies of infiltrating T cell of an individual mouse, based on the analysis of at least 12 sections from anterior, median and
posterior brain portions. Arrows indicate infiltration values at terminal stage while the other dots show infiltration values at 90 dpi.
doi:10.1371/journal.ppat.1002216.g007
Anti-prion T-cells against Scrapie
PLoS Pathogens | www.plospathogens.org 8 September 2011 | Volume 7 | Issue 9 | e1002216is worth noting that, far from being inhibited, specific T cells
proliferated more vigorously in scrapie-infected mice. The
quantitative parameters indicated that the increased proliferation
results from more BV12
+ T cells being activated and undergoing
division than from an increased number of divisions within the 3
days of engraftment. Several reasons could account for the
observed heightened T cell proliferation. Prion-infected APCs
might present a higher density of MHC class II molecules filled
with PrP peptide (signal 1), thus activating T cells more efficiently.
A non-mutually exclusive alternative could be that prion-infected
APCs provide more co-stimulation (signal 2) to T cells than
healthy APCs. Preliminary examination of CD80 and CD86
expression on DCs collected from infected mice did not favor this
latter hypothesis (data not shown), but other co-stimulatory
pathways deserve to be examined. Finally, because PrPc is
mobilized at the immunological synapse [34], the possibility that
transconformed PrPSc might enhance APC function cannot be
totally ruled out, even though this pathway remains difficult to
conceive given the structural properties of the conformer.
In accordance with previous observations [13], sensitized anti-
PrP T cells passively administered into infected mice convey
protectionwithno evidenceof negative side effects. Presently,asfew
as 2610
5 primed BV12
+ T cells delay neurological onset and overt
disease progression to the same extent as 50 times more polyclonal
T cells [13]. The necessity of boosting Tg T cells seems less
imperative than with polyclonal T cells, a fact which is consistent
with the observation that PrP-specific T cells can be re-activated in
vivo by prion infected-APCs or by APCs naturally processing
endogenous PrPc, with no need to boost with exogenous peptide.
The lack of detectable anti-PrP Ab in T-cell transferred mice
argues against the recruitment of resident B cells and the
involvement of Abs in delaying disease progression. As previously
reported [9], anti-PrP B cells differentiating in a PrP+ context,
which is the situation in the recipient, are severely repressed and
few precursors remain available in the periphery. In addition, by
sorting donor cells for maximum purity, we made sure that donor
B cells were not co-transferred. A T-cell-mediated pathway
therefore seems to be the most likely explanation for the observed
Figure 8. Humoral and cell-mediated responses of adoptively transferred T cells. (A) Anti-PrP Abs against cell-surface PrPc. Sera were
collected at 90 and 120 dpi. They are presented collectively since the time of collection had no impact on MFI values. Cell-bound Abs was revealed by
immunofluorescence. Black circles represent sera from non-transferred mice, black diamonds sera from mice transferred with BV12-negative T cells,
gray circles sera from mice transferred with BV12
+ T cells boosted and non-boosted, black triangles are positive controls from PrP– Tg mice primed
with peptide PrP158–187. MFIs (at the 1:100 dilution) between positive controls and the 3 other groups were significantly different by the Kruskal-Wallis
test. (B) In vitro proliferation of spleen T cells collected at 120 dpi from recipient mice. Error bars show the standard deviations of triplicates. Each
column represents an individual mouse. (C) ELISPOT assay of IL-4-secreting T cells collected at 120 dpi. (D) Same as in (C) for IFN-c secretors.
doi:10.1371/journal.ppat.1002216.g008
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engraftment still proliferate in the presence PrP peptide and
produce substantial amounts of IL-4. We previously reported that
a hallmark of polyclonal CD4
+ T cells conveying protection was
the production of both IFN-c and IL-4 [13]. In the present
experimental setting in which small numbers of highly enriched
effectors were transferred, we can further suggest that protection is
conferred by anti-PrP T cells that produce IL-4 rather than IFN-c.
Anti-PrP T cells, which are predominantly biased toward IFN-c
release shortly after priming, seem to evolve with time toward a
Th2 oriented profile. In future experiments, the transfer of
homogeneously polarized lymphocytes should confirm whether a
Th2 profile preferentially conveys protection.
Where and how do T cells precisely halt disease progression? A
reasonable hypothesis, also supported by the reduced content of
PrPSc found in spleens of protected mice, is that PrP-sensitized T
cells exert their prionostatic effects in the periphery, when prions
propagate into secondary lymphoid tissues. The delayed clinical
onset and protracted disease evolution would thus be a direct
consequence of the slowed down lymphoinvasion, as already
demonstrated in situations where the connection between follicular
dendritic cells and nervous endings is perturbed [35] or when DCs
or follicular dendritic cells are temporarily deleted [36,37,38]. Anti-
PrP T cells would preferentially be activated at the sites of prion
expansion such as in germinal centers, upon contact with infected
DCs [39]. They would shift progressively toward a Th2 profile, and
would mobilize agents of innate immunity such as alternatively-
activated macrophages with a capacity to reduce inflammation and
to degrade infectious oligomers in lymphoid follicles [40,41],
thereby retarding lymphoinvasion. But extraneural and neural
invasion are not necessarily connected and the two processes could
evolve independently [42,43]. It is then conceivable that protective
T cells exert their prionostatic effects in parallel, in peripheral
lymphoid tissues and in the CNS. Both the extension of clinical
disease duration and the detection of infiltrating BV12
+ T cells in
the brain of adoptively transferred mice speak in favor of a central
action of T cells. Beneficial effects of IL-4-producing T cells have
been described in various CNS pathological conditions as well as in
physiological situations of memory acquisition [44,45,46]. Microg-
lial cells or blood borne macrophages alternatively activated by Th2
T cells might retain their innate capacity to degrade pathological
oligomers or fibrils [47] while protecting neurons from PrPSc-
mediated toxicity. A recent study showing that prion propagation
and neurotoxicity are dissociated processes [48] further supports the
idea that the protective role of alternatively-activated effectors of
innate immunity may not be confined to phagocytosis of amyloid
aggregates only. Microglia activated by IL-4 induces oligodendro-
genesis from adult stem cells. This effect is mediated, at least in part,
by insulin-like growth factor-1 [49]. IL-4 can also counteract, in a
dose-protective manner, the harmful effect of microglia activated by
LPS. The mechanism by which IL-4 exerts its neuroprotective
effects, involves the decrease of TNF-a and nitric oxide production
[50]. The role of IL-4 in regulating CNS inflammation was also
investigated in experimental autoimmune encephalomyelitis, a
mouse model for multiple sclerosis. Ponomarev et al. showed that
mice deficient in IL-4 had exacerbated neurological symptoms
associated with a significantincreaseininfiltratinginflammatorycell
number. CNS-resident microglial cells expressed in an IL-4
dependent manner the protein Ym1, a marker of alternatively
activated macrophages [51].
In conclusion, our present results provide further support in
favor of a positive role of cell-mediated immunity in TSE. T cells
are not necessarily detrimental. They can be useful depending on
their differentiation profile and, most likely too, on the stage of
disease evolution. More generally, the success of immunothera-
peutic strategies against neurodegenerative conditions will depend
on our capacity to draw a clear line between useful and harmful
processes and to set up beneficial synergies between the different
arms of innate and acquired immunity.
Materials and Methods
Ethic Statement
All animal procedures were carried out in strict accordance with
the French legislation (Rural Code articles L 214-1 to L 214-122
and associated penal consequences) and European Treaty ETS 123
(1986). They were approved by the Regional Ethic Committee
‘‘Charles Darwin’’ to which the animal facility is affiliated.
Mice
PrP– mice (Prnp
0/0) [52] were propagated on a C57BL/6 (B6)
background [13]. Ly5.1 and CD3e
0/0 mice were also on a B6
background.
Generation of TCR-b Transgenic Mice
A rearranged TCR b-chain (TRBV12-1-01*/TRBD1-01*/
TRBJ1-4-02* (http://imgt.cines.fr)) was cloned from a T hybrid-
oma generated by fusion of T cells from PrP– mice immunized
with peptide PrP158–187 [18]. Genomic DNA was inserted into an
expression cassette containing the Cd4 promoter [15]. The Cd8
silencer, originally present, was ultimately excised from the
construct. The backbone vector was a PNNO3 plasmid, and the
transgene was inserted at a SalI restriction site and excised with
NotI. Purified DNA fragment was microinjected into WT B6 eggs
(SEAT facility, Villejuif, France). Founders were identified by tail
PCR, and the selected founder was mated with PrP+ and PrP–
breeders to establish two independent lines. The transgene was
kept heterozygous in both progenies.
Flow Cytometry Analyses
Transgene expression was followed with anti-Vb5.1/5.2 Ab
(clone MR9-4) conjugated to FITC (BD Biosciences, Pont-de-
Claix, France). Other reagents were CD4-PE, CD8-PerCP-Cy5.5,
CD19-PE, and Vb5.1/5.2-biotinylated revealed by streptavidin-
APC, all from BD Biosciences. Samples were analyzed with BD
CellQuest or FlowJo (TreeStar, Ashland, Oregon, USA).
In Vivo Priming and Enrichment of CD4
+ T Cells
Mice received 50 mg of peptide PrP158–187 in complete Freund’s
adjuvant. Spleens and LNs were collected 10 days later. CD4
+ T
cells were enriched above 90% purity using a negative isolation kit
according to the manufacturer’s recommendations (Dynal,
Invitrogen, Oslo, Norway).
Functional in Vitro Assays
CD4
+ T cells were assayed for proliferation in micro-culture
plates containing mitomycin-C-treated PrP– spleen cells and
various concentrations of PrP158–187 as previously described [18].
Cultures were pulsed overnight with tritiated thymidine after a
variable number of days (indicated in figure legends). Lympho-
kine-secreting T cells were enumerated by ELISPOT assay
according to standard procedures [34].
Follow-up of CD4
+ T Cell Activation in Vivo by CFSE
Staining
Enriched CD4
+ T cells (1610
7 cells) were labeled with 2.5 mM
of CFSE (Molecular Probes, Invitrogen, Cergy-Pontoise, France)
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and resuspended in PBS. Cells were injected i.v. at 2610
6 per
mouse. Specific proliferation was measured at day 3 on a LSR2
cytometer (BD). Cells were also stained with Vb5-biotinylated-
streptavidin2PerCP-Cy5.5, CD4-APC-Cy5.5 and CD45.2-APC.
Results are expressed as ‘‘% divide’’ (% of cells which underwent
divisions) or ‘‘division index’’ (the average number of divisions that
a cell undergoes, including cells that did not divide).
Immunoscope Analysis of TCR a-Chain Repertoires
The diversity of a rearrangements was analyzed by immuno-
scope [53]. TRBV12
+ T cells were sorted on a cell sorter (FACS-
ARIA BD). Total RNA was prepared using a micro kit (RNeasy,
QIAGEN, Courtaboeuf, France), and cDNA was synthesized with
SuperScript II Reverse Transcriptase (Invitrogen). The distribu-
tion of TCR-Va germline genes clustered into 20 families (IMGT
nomenclature) was obtained by PCR. The relative usage of each
Va family was calculated according to the formula:
U(AVy)~
X x~21
x~1
2 Ct(x){Ct(y) ðÞ
in which Ct(x) is the fluorescent threshold cycle number measured
for a Va (y) family.
For immunoscope profiles, products were subjected to run-off
reactions for three cycles with a nested fluorescent primer specific
for the constant region. The fluorescent products were separated
and analyzed using an ABI-PRISM 3730 DNA analyzer. The size
and intensity of each band were analyzed with ‘‘Immunoscope
software’’ [53] further adapted to the capillary sequencer [54].
Fluorescence intensities were plotted in arbitrary units on the y
axis, and CDR3 lengths (in amino acids) on the x axis.
Monitoring of Scrapie Infection
Mice of both sexes, between 8 to 12 weeks of age, were infected
i.p. with a brain homogenate of 139A prions containing 2610
4
LD50. Mice were monitored twice a week for gait control on a set
of parallel bars [39].
Detection of PK-resistant PrP by Western Blot
Spleens and brains collected at various time points post-
infection were homogenized with the Ribolyser method and
adjusted at 10% w/v in PBS plus a cocktail of anti-proteases.
Precipitation with sodium phosphotungstic acid (Sigma) was
performed as previously described [12]. Aliquots equivalent to
6 mg were PK-digested or left undigested. PK (proteinase K,
Roche) was applied at 50 mg/ml, at 37uC for 30 min. Samples
were run on 12.5% SDS-PAGE. PrP was revealed with Ab SAF-
84 at 1/5000 (generously provided by Dr. J. Grassi, CEA). Signal
was captured with a Fujifilm LAS3000 camera and quantified with
a Fujifilm software program.
Serological Detection of Abs against Native PrPc
Abs against native membrane-bound PrPc were measured by
indirect immunofluorescence [18]. Sera were assayed at three-fold
consecutive dilutions. Results are shown as geometric mean
fluorescence intensities (MFIs).
Histology
Hematoxylin eosin staining was performed on paraffin embed-
ded sections at 5 mm, according to standard procedures. PrPc
staining was performed on frozen sections of spleens and brains.
Endogenous peroxydases were saturated with a solution of PBS-
H2O2 at 0.3% final (Sigma, France) for 30 minutes. PrPc was
labelled with a biotinilated SAF-83 Ab (gift of Dr. J. Grassi) at
5 mg/ml final concentration in tween-PBS for 1 hour at room
temperature. Revelation was made with a horseradish-peroxidase
streptavidin conjugate (GE Healthcare, Pittsburgh, USA) followed
by incubation with a solution of diaminobenzidine (Diagnostics
Biosystems, Pleasantville, USA).
Infiltrating T lymphocytes were identified on frozen crosswise
brain sections as previously described [13]. Ten mm thick sections
were air dried, fixed in acetone at 4uC and stained with an anti-
CD3 rabbit monoclonal Ab (clone SP7) (Thermo Fisher Scientific,
Fremont, USA) at 5 mg/ml. Revelation was achieved with a goat
anti rabbit alexa fluor 488 (Invitrogen, Cergy-Pontoise, France).
Microphotographs were taken with an Olympus BX61
microscope equipped with an Olympus DP71 camera. Lens
magnification is given in the legends to figures. Section areas were
calculated with imagej software (http://rsbweb.nih.gov/ij).
Statistical Analysis
Analyses were performed with GraphPad software (San Diego,
CA, USA).
Supporting Information
Figure S1 Percentages of CD4
+, CD8
+, and B cells in Tg
mice. Percentages were measured by flow cytometry. CD4
+ T
cell proportion in Tg mice is slightly but significantly reduced
(p,0.001 by ANOVA and p,0.01 by Bonferroni’s multiple
comparison test between Tg PrP+ and PrP–, and WT mice for n
comprised between 5 and 14).
(TIF)
Figure S2 Normal development of germinal centers and
PrPc expression in secondary lymphoid organs of Tg
mice. (A) H&E staining of paraffin sections of spleens from WT
and Tg mice on a PrP+ and PrP– background. Germinal centers
in spleens of Tg mice have a normal size and architecture (10X).
(B) Immunohistochemical staining of PrPc on frozen sections of
spleens from WT and Tg mice (40X).
(TIF)
Figure S3 PrPc expression is normal in PrP+ Tg mice.
(A) Immunohistochemical staining ofPrPcwasperformed onfrozen
sections of cerebellum as described in Materials and Methods. PrPc
accumulates in the white matter (10X). (B) Anti-PrPc labeling was
performed on total brain cells mechanically dispersed in the
presence of DNAase. Cell suspensions were incubated with a FITC-
conjugated SAF61 Ab at 10 mg/ml. The overlay represents
respectively brain cells of a WT PrP+ mouse (green line), a PrP+
Tg mouse (dark pink line) and a PrP– Tg mouse (dashed blue line).
(TIF)
Figure S4 Higher frequency of IFN-c secretors among
CD4
+ T cells from PrP– Tg versus WT mice. T cells were
collected from mice primed with peptide PrP158-187 10 days earlier
and subsequently incubated in vitro for 24h as described in
Materials and Methods. Each number on the horizontal axes
corresponds to an individual mouse. Error bars show standard
error of average number of spots in at least 3 wells. The
experiment was repeated 3 times.
(TIF)
Figure S5 Significant increase in the percentage of CD4
+
BV12
+ T cells in lymph nodes after priming with peptide
PrP158–187. Cells were stained as described in Materials and
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of 3 experiments. Statistical analysis was performed using one way
variance analysis and Bonferroni’s multiple comparison tests.
(TIF)
Figure S6 An overview of TRAV family usage by BV12
+
CD4
+ T cells from Tg primed or naive mice on a PrP+ or
PrP– background. (A) TRAV profiles of naive BV12
+ T cells
from PrP– mice. (B) TRAV profiles of naive BV12
+ T cells from
PrP+ mice. (C) TRAV profiles of primed BV12
+ T cells from PrP–
mice. (D) TRAV profiles of primed BV12
+ T cells from PrP+ mice.
(TIF)
Figure S7 PrPSc content at terminal stage. (A) Western
blots were performed as described in Materials and Methods on
brains of mice culled at their respective terminal stage. Mice #1
and #2 belonged to the group transferred with BV12-negative T
cells. Mouse #3 was transferred with BV12
+ T cells with no boost
and mice #4 and #5 received BV12
+ T cells further boosted. (B)
Absence of detectable PrPSc in the spleen and the brain of the
infected mouse which had received BV12
+ T cells plus boosts and
was still free of symptoms at 350 dpi. The tissues culled at terminal
stage of a non-treated control mouse and processed in parallel
serve as a positive control.
(TIF)
Figure S8 Expansion into CD3e
o/o recipient mice of
transferred BV12
+ CD4
+ T cells. Blood samples were
collected at 90 dpi. Each quadrant represents an individual
mouse. Percentages of BV12
+ T cells in quadrants are relative to
total number CD4
+ T lymphocytes.
(TIF)
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